Resource Summary Report

Generated by dkNET on Sep 8, 2026

786-O

RRID:CVCL_1051
Type: Cell Line

Proper Citation

RRID:CVCL_1051

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1051

Proper Citation: RRID:CVCL_1051

Description: Cell line 786-O is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Renal cell carcinoma

Defining Citation: PMID:721102, PMID:1010528, PMID:2041050, PMID:6244232, PMID:7915601, PMID:9331090, PMID:10700174, PMID:15585611, PMID:15748285, PMID:17088437, PMID:19372543, PMID:20164919, PMID:22068913, PMID:22185343, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:22949125, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24670534, PMID:25485619, PMID:25877200, PMID:25894527, PMID:25984343, PMID:26589293, PMID:26972028, PMID:27141528, PMID:27377824, PMID:27397505, PMID:27807467, PMID:27993170, PMID:28196595, PMID:28489074, PMID:30260228, PMID:30894373, PMID:31068700, PMID:31267758, PMID:31733513, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 786-O

Synonyms: 786-o, 786O, 786-0, 786.O, 786-O RCC, RCC 786-O, RCC_7860, RCC 7860, 7860, 786-0WT

Cross References: BTO:BTO_0003781, CLO:CLO_0001486, EFO:EFO_0005707, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1932, BCRC:60243, BioGRID_ORCS_Cell_line:502, BioSample:SAMN03471906, BioSample:SAMN10988199, cancercelllines:CVCL_1051, CCRID:1101HUM-PUMC000243, CCRID:3101HUMSCSP5059, CCRID:3101HUMTCHu186, CCRID:4201HUM-CCTCC00159, CCRID:5301HUM-KCB09014YJ, CCTCC:GDC0159, Cell_Model_Passport:SIDM00125, ChEMBL-Cells:CHEMBL3308018, ChEMBL-Targets:CHEMBL613102, CLS:300107, Cosmic:687936, Cosmic:875874, Cosmic:897461, Cosmic:905947, Cosmic:972929, Cosmic:974305, Cosmic:982276, Cosmic:1044259, Cosmic:1092589, Cosmic:1175848, Cosmic:1305372, Cosmic:1312360, Cosmic:1481416, Cosmic:1998431, Cosmic:2036676, Cosmic:2520637, Cosmic:2663796, Cosmic-CLP:905947, DepMap:ACH-000649, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS261AAA, ENCODE:ENCBS413VCR, ENCODE:ENCBS807WMR, GDSC:905947, GEO:GSM2128, GEO:GSM50226, GEO:GSM50290, GEO:GSM482711, GEO:GSM743488, GEO:GSM750838, GEO:GSM799371, GEO:GSM799377, GEO:GSM799434, GEO:GSM843437, GEO:GSM846283, GEO:GSM886845, GEO:GSM887909, GEO:GSM1153444, GEO:GSM1177874, GEO:GSM1177875, GEO:GSM1177876, GEO:GSM1181296, GEO:GSM1181322, GEO:GSM1669572, GEO:GSM2124635, IARC_TP53:18076, IARC_TP53:28222, IZSLER:BS TCL 124, KCB:KCB 200941YJ, LiGeA:CCLE_806, LINCS_LDP:LCL-1773, Lonza:1087, MetaboLights:MTBLS737, NCI-DTP:786-0, PharmacoDB:7860_28_2019, PRIDE:PXD000335, PRIDE:PXD000589, PRIDE:PXD001493, PRIDE:PXD003105, PRIDE:PXD003539, PRIDE:PXD005453, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1051, PubChem_Cell_line:CVCL_1051, SKY/M-FISH/CGH:2782, Ubigene:YC-C113, Wikidata:Q54604950

ID: CVCL_1051

Record Creation Time: 20220427T215100+0000

Record Last Update: 20260905T184340+0000

Ratings and Alerts

No rating or validation information has been found for 786-O.

No alerts have been found for 786-O.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1526 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Koh J, et al. (2026) ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. Cancer research, 86(7), 1676.

Chen Y, et al. (2026) USP15 stabilizes c-Myc to drive sunitinib resistance by suppressing cuproptosis in clear cell renal cell carcinoma. Cell reports, 45(5), 117328.

Shi H, et al. (2026) OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma. Cell death & disease, 17(1).

Koochaki P, et al. (2026) Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism. The EMBO journal, 45(11), 3763.

Alhourani F, et al. (2026) Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer. Cancer research, 86(1), 236.

Zhang C, et al. (2026) Quantification of Single-Cell Cysteine Using an Electrochemical Nanosensor for Predicting Tumor Disulfidptosis Susceptibility. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(13), e23478.

Zhu X, et al. (2026) KIAA1429 promotes clear cell renal cell carcinoma progression by regulating MYC mRNA stability. iScience, 29(4), 115198.

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research, 86(9), 2237.

Abou Alaiwi S, et al. (2026) Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability. Cell reports, 45(2), 116968.

Hatayama T, et al. (2026) Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma. Urologic oncology, 44(8), 108.

Wang C, et al. (2026) USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. iScience, 29(5), 115808.

Li Y, et al. (2026) Integrating Bulk and Single-Cell RNA-Seq Reveals Glycolysis-Associated Macrophages and Its Related Tumor Subgroup Signatures to Predict Prognosis and Therapy in Clear Cell Renal Cell Carcinoma. Human mutation, 2026, 3125551.

Liu X, et al. (2026) High throughput screening identifies sanguinarine chloride as a multi-faceted therapeutic agent for PRCC-TFE3 rRCC by targeting lactylation-driven VEGFB-VEGFR2 signaling and PMN-MDSC infiltration. Journal of advanced research.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. iScience, 29(7), 116386.

Gu S, et al. (2026) MAGI3 deficiency unleashes ??-catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC. Cell death & disease, 17(1).

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. Cell death & disease, 17(1).

Li YR, et al. (2026) Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. STAR protocols, 7(1), 104340.

Richmond G, et al. (2026) Large extracellular vesicles regulate endothelial angiogenic potential via paracrine and autocrine signaling. The Journal of biological chemistry, 302(3), 111193.

Heritz JA, et al. (2026) Targeting and dissociating HIF2?? from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. Communications medicine, 6(1), 91.

Paparella AT, et al. (2026) Pharmacologic and Oncohistone Inhibition of SETD2 Converge on Genomic Instability. Cancers, 18(5).